{
    "clinical_study": {
        "@rank": "83856", 
        "acronym": "AGO01", 
        "arm_group": [
            {
                "arm_group_label": "needle 4 mm gauge 33", 
                "arm_group_type": "Experimental", 
                "description": "Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)"
            }, 
            {
                "arm_group_label": "needle 4 mm gauge 32", 
                "arm_group_type": "Active Comparator", 
                "description": "Needle for insulin pen, 4 mm long and with a diameter of 32 gauge"
            }
        ], 
        "brief_summary": {
            "textblock": "During the last years, even more little needles are used for the injection of sub cutaneous\n      insulin, for the diabetes therapy.\n\n      The aim of this study is to evaluate the non inferiority of a new needle, smaller than\n      another needle, in terms of hematic levels od fructosamine, an indicator of glycemic\n      control."
        }, 
        "brief_title": "Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Type 1 Diabetes", 
            "Type 2 Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with type 1 or type 2 diabetes\n\n          -  both males and females\n\n          -  age >=18 anni\n\n          -  insulin treatment from at least 6 months\n\n          -  signed informed consent\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  incapacity for filling in the questionnaires\n\n          -  every illness or condition that, according to the investigator, could interfere with\n             the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745549", 
            "org_study_id": "AGO01"
        }, 
        "intervention": [
            {
                "arm_group_label": "needle 4 mm gauge 33", 
                "intervention_name": "Needle for insulin pen, 4 mm long and with a diameter of 33 gauge", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "needle 4 mm gauge 32", 
                "intervention_name": "Needle for insulin pen, 4 mm long and with a diameter of 32 gauge", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes", 
            "insulin therapy", 
            "needle"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Treviglio", 
                        "country": "Italy", 
                        "state": "BG", 
                        "zip": "24047"
                    }, 
                    "name": "UO Malattie Metaboliche e Diabetologia - Ospedale di Treviglio-Caravaggio"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "state": "BS", 
                        "zip": "25123"
                    }, 
                    "name": "UO Diabetologia per Trattamento e Educazione dei Diabetici - Spedali Civili di Brescia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mariano Comense", 
                        "country": "Italy", 
                        "state": "CO", 
                        "zip": "22066"
                    }, 
                    "name": "U.O.S. Diabetologia e Malattie Metaboliche - PO Cant\u00f9 - Mariano Comense"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00157"
                    }, 
                    "name": "Struttura Complessa Dietologia-Diabetologia Malattie Metaboliche - Ospedale Pertini"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy, Safety and Satisfaction of the New Pen Needle 33G x 4 mm 33G x 4 mm: Cross-over Randomized Controlled Clinical Trial. Studio AGO 01", 
        "overall_official": {
            "affiliation": "Consorzio Mario Negri Sud", 
            "last_name": "Antonio Nicolucci, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "hematic fructosamine levels", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline in fructosamine levels after 3 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745549"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Consorzio Mario Negri Sud", 
            "investigator_full_name": "Antonio Nicolucci", 
            "investigator_title": "Dr Antonio Nicolucci, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "mean amplitude of glucose excursions (MAGE)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in MAGE after 3 weeks of treatment"
            }, 
            {
                "description": "visual analogic scale (VAS) 1-10", 
                "measure": "pain", 
                "safety_issue": "No", 
                "time_frame": "questionnaire at the end of the treatments (at 6 weeks)"
            }, 
            {
                "description": "visual scale", 
                "measure": "leakage at the site injection", 
                "safety_issue": "No", 
                "time_frame": "number of episodes of leakage during the treatment (3 weeks)"
            }, 
            {
                "measure": "hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "number of episodes of hypoglycemia during the treatment (3 weeks)"
            }, 
            {
                "measure": "insulin dosage", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in insulin dosage after 3 weeks of treatment"
            }, 
            {
                "measure": "patient's weight", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in weight after 3 weeks of treatment"
            }, 
            {
                "description": "VAS scale", 
                "measure": "patient's satisfaction", 
                "safety_issue": "No", 
                "time_frame": "questionnaire at the end of the treatments (at 6 weeks)"
            }
        ], 
        "source": "Consorzio Mario Negri Sud", 
        "sponsors": {
            "collaborator": {
                "agency": "Artsana SpA", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Consorzio Mario Negri Sud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}